By REUTERS
A federal appeals court in New York ruled on Friday that Actavis cannot withdraw its top-selling Alzheimer’s disease drug from the market in favor of a more expensive extended-release version.
Published: May 23, 2015 at 12:00AM
from NYT Business Day http://ift.tt/1F6PoS5
from WordPress http://ift.tt/1HA58Qv
via Hadi Aboukhater
No comments:
Post a Comment